

# How Should LAA Closure Devices be Integrated into Clinical Practice?

David R. Holmes, Jr., M.D.
Mayo Clinic, Rochester
TCTAP 2014
Seoul, Korea
April 2014

#### **Presenter Disclosure Information**

David R. Holmes, Jr., M.D.

"How Should LAA Closure Devices be Integrated into Clinical Practice?"

The following relationships exist related to this presentation:

Both Mayo Clinic and I have a financial interest in technology related to this research. That technology has been licensed to Boston Scientific.







- Where will the patients come from?
  - General internal medicine/family practice
  - Geriatrics
  - Neurology
  - Thrombophilia clinics
  - Gastroenterology
  - General cardiology
  - Interventional cardiology
  - Electrophysiology




- How will they get to you?
  - Inpatient or outpatient services
  - Arrhythmia clinics
  - Structural heart disease clinics
  - Cardioversion units



- Patient protocols
  - Need for CT
  - Timing of TEE for thrombus screening
  - Bridging before and after
  - Pre TS medications
  - Adjunctive therapy





#### **Which Patients?**

- High risk for bleeding
- Unable to take warfarin or a NOAC
- Chooses not to take warfarin or a NOAC
- Issues of convenience "get it over with"



- Stratify risk/benefit issues
  - Balance bleeding versus stroke
  - Balance short-term procedural risks versus longer-term risks/gains
- Patient education
- Patient outreach



#### **LAA and Clinical Practice**

- Who will perform the procedure?
  - Interventional Cardiology and ECHO
  - Electrophysiology and ECHO
  - Team-based care Interventional cardiology, EP, ECHO
- Where will it be performed?
  - Catheterization laboratory
  - EP laboratory
- Will an industry device specialist always be needed?



### LAA and Clinical Practice How Will it be Done?

- TEE guidance
- ICE guidance
- Angiographic guidance
- CT guidance robotically



#### **Patients with AF**

**Screening Phase** 

Prior History
Chronicity
Triggers
Embolic events
Hx bleeding
Prior Rx
AC profile

Evaluation of Structural

Heart Disease

ECHO

NVAF vs VAF

LAA anatomy & function


RO persistent thrombus

CT – LAA shape/size

Formal stroke
assessment
CHADS<sub>2</sub>VASC
Bleeding assessment
HAS-BLED




#### **Patients with AF**





### Patients with AF LAA Occlusion



- Personnel identified
- Equipment available
- EP vs IC



### Patients with AF LAA Occlusion

**Post Procedural Management** 

Requirements for adjunctive medications

Continued treatment of or evaluation of procedural complications

Inpatient vs outpatient



